XML 46 R33.htm IDEA: XBRL DOCUMENT

Operating Segments (Tables)

9 Months Ended

Sep. 30, 2021

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The table below presents certain financial information of our operating segments for the three and nine months ended September 30, 2021 and 2020 (in thousands).

Segment Reporting for the Quarter Ended September 30, 2021

		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
Revenue from external customers		$	8,893			$	6,904				—			$	15,797			$	—			$	15,797
Intercompany revenues			220				5				—				225				—				—
Gross profit (negative gross profit)			2,487				(263	)			—				2,224				—				2,224
Research and development			52				18				162				232				11				243
Interest income			—				—				—				—				2				2
Interest expense			(51	)			(1	)			—				(52	)			(25	)			(77	)
Interest expense-financing fees			—				—				—				—				(11	)			(11	)
Depreciation and amortization			319				85				—				404				5				409
Segment income (loss) before income taxes			1,317				(984	)			(162	)			171				(1,626	)			(1,455	)
Income tax expense (benefit)			1				—				—				1				(2,837	)			(2,836	)⁽⁵⁾
Segment income (loss)			1,316				(984	)			(162	)			170				1,211				1,381
Expenditures for segment assets			482				—				—				482				—				482	⁽²⁾

Segment Reporting for the Quarter Ended September 30, 2020

		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
Revenue from external customers		$	7,066			$	23,106				—			$	30,172			$	—			$	30,172
Intercompany revenues			226				6				—				232				—				—
Gross profit			1,094				3,656				—				4,750				—				4,750
Research and development			49				7				81				137				20				157
Interest income			—				—				—				—				28				28
Interest expense			(34	)			(3	)			—				(37	)			(50	)			(87	)
Interest expense-financing fees			—				—				—				—				(58	)			(58	)
Depreciation and amortization			373				97				—				470				8				478
Segment income (loss) before income taxes			280				2,813				(81	)			3,012				(1,664	)			1,348
Income tax (benefit) expense			(170	)			2				—				(168	)			35				(133	)
Segment income (loss)			450				2,811				(81	)			3,180				(1,699	)			1,481
Expenditures for segment assets			95				24				—				119				3				122	⁽³⁾

Segment Reporting for the Nine Months Ended September 30, 2021

		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
Revenue from external customers		$	24,094			$	30,981				—			$	55,075			$	—			$	55,075
Intercompany revenues			1,199				44				—				1,243				—				—
Gross profit			4,845				701				—				5,546				—				5,546
Research and development			142				50				311				503				35				538
Interest income			—				—				—				—				23				23
Interest expense			(88	)			(9	)			—				(97	)			(112	)			(209	)
Interest expense-financing fees			—				—				—				—				(28	)			(28	)
Depreciation and amortization			939				255				—				1,194				14				1,208
Segment income (loss) before income taxes			1,669				(1,721	)			(311	)			(363	)			987	⁽⁴⁾			624
Income tax (benefit) expense			(13	)			10				—				(3	)			(2,837	)			(2,840	)⁽⁵⁾
Segment income (loss)			1,682				(1,731	)			(311	)			(360	)			3,824				3,464
Expenditures for segment assets			1,109				14				—				1,123				9				1,132	⁽²⁾

Segment Reporting for the Nine Months Ended September 30, 2020

		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
		Treatment				Services				Medical				Segments Total				Corporate ⁽¹⁾				Consolidated Total
Revenue from external customers		$	24,469			$	52,610				—			$	77,079			$	—			$	77,079
Intercompany revenues			879				19				—				898				—				—
Gross profit			5,533				7,167				—				12,700				—				12,700
Research and development			194				119				221				534				64				598
Interest income			1				—				—				1				111				112
Interest expense			(80	)			(13	)			—				(93	)			(213	)			(306	)
Interest expense-financing fees			—				—				—				—				(187	)			(187	)
Depreciation and amortization			912				259				—				1,171				18				1,189
Segment income (loss) before income taxes			2,577				5,162				(221	)			7,518				(4,597	)			2,921
Income tax (benefit) expense			(165	)			2				—				(163	)			35				(128	)
Segment income (loss)			2,742				5,160				(221	)			7,681				(4,632	)			3,049
Expenditures for segment assets			1,095				385				—				1,480				8				1,488	⁽³⁾

⁽¹⁾

Amounts reflect the activity for corporate headquarters not included in the segment information.

⁽²⁾

Net of financed amount of $271,000 and $348,000 for the three and nine months ended September 30, 2021, respectively.

⁽³⁾

Net of financed amount of $751,000 and $883,000 for the three and nine months ended September 30, 2020, respectively.

⁽⁴⁾

Amounts includes approximately $5,381,000 of “Gain on extinguishment of debt” recorded in connection with the Company’s PPP Loan which was forgiven by the SBA effective June 15, 2021 (see “Note 8 – Long Term Debt – PPP Loan” for information of this loan forgiveness).

⁽⁵⁾

Includes tax benefit recorded in amount of approximately $2,351,000 resulting from release of valuation allowance on the Company’s deferred tax assets (see “Note 12 – Income Taxes” below a discussion of this tax benefit).